The small number and narrow focus of the survey questions in this study, as well as the small unrepresentative sample of psychiatrists surveyed, limit the overall value and interpretation of the results. Despite these limitations, the authors know more about this group of psychiatrists than I know about Dr. R. I know nothing about Dr. R, except that he is not a psychiatrist and that he apparently believes that my prescribing fluphenazine is behind the times. Second-generation antipsychotics have been actively investigated for conditions other than schizophrenia, and some have gained approval for treatment of mood disorders. Consequently, they are being marketed more widely to the general public as well as to nonpsychiatrists. Although I do not know what sources of information influence Dr. R's opinion about antipsychotics for schizophrenia, it would surprise me if he, as a primary care physician, reads relevant research reports or practice guidelines. However, I think it is likely that drug representatives visit his office. If they do visit Dr. R, is he less likely to be optimistic toward the second-generation antipsychotics than the psychiatrists surveyed by Arbuckle and colleagues?